Keya Medical announced today that it has received a strategic investment from Kunlun Wanwei Group, IDG Capital, Shanghai Guofang Parent Fund, and Yahui Capital.
On January 15, 2020, the National Medical Products Administration in China issued the registration certificate approving DeepVessel FFR for clinical use.
Keya Medical Attends 10th Summit on Scientific and Technological Innovation in Major Disease Control
The 10th Summit on Scientific and Technological Innovation in Major Disease Control sponsored by the Beijing Municipal Science and Technology Commission, took place on Dec. 21, 2019 at the National Convention Center.
The Future Medical 100 Annual Conference was held Dec. 20, 2019 in Beijing Jiuhua Villa. Keya Medical was among the companies listed on the Top 100 List, and DEEPVESSEL FFR made the list of the Top 5 FFR Products in China.
Keya Medical’s non-invasive CT-FFR product, DEEPVESSEL FFR, was officially implemented in Shunde Hospital of Southern Medical University.
Keya Medical’s non-invasive coronary evaluation software, DEEPVESSEL FFR, was successfully installed at China Civil Aviation General Hospital on Dec. 2, 2019.
Keya Medical announced on September 21, 2018 that DEEPVESSEL FFR received ISO 13485:2016 certification for Medical Device and Quality Managements Systems as well as its CE Mark Certification after a series of on-site audits and evaluations by its notified body, DEKRA.